What smart money is saying about Cabaletta Bio
CABA
No fund has written a full thesis on Cabaletta Bio in our archive, but 1 fund letter reports a position in it — most recently Jacob Funds Internet, Small Cap Growth and Discovery Funds in July 2026.
Get an email when a fund writes about it
1
Reported positions
0
Bought
0
Sold
1
Letter
Position history
Every position in Cabaletta Bio on record in the archive was reported in Q3 2026, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 0 |
Fund activity · 1 position
“Kyverna is a small biotech company developing cell therapies that aim to “reset” the immune system in severe autoimmune diseases. Its lead opportunity is in stiff person syndrome, a rare and debilitating neurologic disease with no approved treatment, where early patient data showed meaningful improvement in symptoms and daily function for some patients. Kyverna, along with Fund holdings Cabaletta Bio and Cartesian Therapeutics, are all trying to prove out this approach, which could potentially apply to larger autoimmune markets, including myasthenia gravis and multiple sclerosis.”
Cabaletta Bio
Read the letters behind these Cabaletta Bio positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger